Intravenous Infusions Plc (GHSE:IIL)
Ghana
· Delayed Price · Currency is GHS 0.0500
0.00 (0.00%)
At close: Feb 16, 2026
Intravenous Infusions Income Statement
Financials in millions GHS. Fiscal year is January - December.
Millions GHS. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 9.3 | 24.94 | 31.42 | 20.36 | 22.67 | Upgrade
|
| Revenue Growth (YoY) | -62.70% | -20.61% | 54.34% | -10.21% | 9.69% | Upgrade
|
| Cost of Revenue | 7.37 | 13.39 | 14.14 | 11.6 | 12.04 | Upgrade
|
| Gross Profit | 1.94 | 11.55 | 17.28 | 8.76 | 10.63 | Upgrade
|
| Selling, General & Admin | 8.4 | 10.07 | 9.96 | 11.39 | 8.86 | Upgrade
|
| Amortization of Goodwill & Intangibles | - | 0.01 | 0.01 | 0 | - | Upgrade
|
| Operating Expenses | 9.01 | 10.73 | 10.76 | 11.96 | 9.41 | Upgrade
|
| Operating Income | -7.07 | 0.82 | 6.52 | -3.21 | 1.23 | Upgrade
|
| Interest Expense | -0.1 | -0.14 | -0.72 | -0.39 | -0.15 | Upgrade
|
| Other Non Operating Income (Expenses) | 2.03 | -1.17 | -2.35 | 0.06 | 0.36 | Upgrade
|
| EBT Excluding Unusual Items | -5.15 | -0.49 | 3.44 | -3.54 | 1.43 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | 0.01 | 0.05 | 0 | - | Upgrade
|
| Pretax Income | -5.15 | -0.49 | 3.49 | -3.53 | 1.43 | Upgrade
|
| Income Tax Expense | 0.03 | 0.16 | 0.95 | -0.02 | 0.29 | Upgrade
|
| Net Income | -5.18 | -0.64 | 2.54 | -3.51 | 1.15 | Upgrade
|
| Net Income to Common | -5.18 | -0.64 | 2.54 | -3.51 | 1.15 | Upgrade
|
| Net Income Growth | - | - | - | - | -20.99% | Upgrade
|
| Shares Outstanding (Basic) | 276 | 274 | 274 | 274 | 274 | Upgrade
|
| Shares Outstanding (Diluted) | 276 | 274 | 274 | 274 | 274 | Upgrade
|
| Shares Change (YoY) | 0.44% | - | - | - | - | Upgrade
|
| EPS (Basic) | -0.02 | -0.00 | 0.01 | -0.01 | 0.00 | Upgrade
|
| EPS (Diluted) | -0.02 | -0.00 | 0.01 | -0.01 | 0.00 | Upgrade
|
| EPS Growth | - | - | - | - | -21.00% | Upgrade
|
| Free Cash Flow | -1.41 | 6.26 | 2.39 | 0.45 | -3.86 | Upgrade
|
| Free Cash Flow Per Share | -0.01 | 0.02 | 0.01 | 0.00 | -0.01 | Upgrade
|
| Dividend Per Share | - | 0.003 | 0.004 | - | - | Upgrade
|
| Dividend Growth | - | -30.00% | - | - | - | Upgrade
|
| Gross Margin | 20.83% | 46.31% | 55.01% | 43.02% | 46.91% | Upgrade
|
| Operating Margin | -76.04% | 3.28% | 20.74% | -15.76% | 5.42% | Upgrade
|
| Profit Margin | -55.69% | -2.58% | 8.10% | -17.24% | 5.06% | Upgrade
|
| Free Cash Flow Margin | -15.20% | 25.09% | 7.59% | 2.22% | -17.03% | Upgrade
|
| EBITDA | -6.46 | 1.47 | 7.31 | -2.64 | 1.76 | Upgrade
|
| EBITDA Margin | -69.44% | 5.89% | 23.27% | -12.98% | 7.79% | Upgrade
|
| D&A For EBITDA | 0.61 | 0.65 | 0.79 | 0.56 | 0.54 | Upgrade
|
| EBIT | -7.07 | 0.82 | 6.52 | -3.21 | 1.23 | Upgrade
|
| EBIT Margin | -76.04% | 3.28% | 20.74% | -15.76% | 5.42% | Upgrade
|
| Effective Tax Rate | - | - | 27.17% | - | 19.97% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.